Viking Global Takes 9.9% Stake in Standard BioTools

TL;DR

**Viking Global just bought 9.9% of Standard BioTools, big institutional vote of confidence!**

AI Summary

Viking Global Investors LP, a prominent investment firm, reported on January 9, 2024, that they hold 10,000,000 shares of Standard BioTools Inc. (formerly Fluidigm Corp.) common stock, representing 9.9% of the company. This significant stake, valued at approximately $10 million based on a hypothetical $1.00 share price, indicates Viking Global's strong conviction in the laboratory analytical instruments company. This matters to investors because a large institutional investment suggests a vote of confidence in Standard BioTools' future prospects and could attract further investor interest.

Why It Matters

A major institutional investor like Viking Global taking a substantial position can signal market confidence and potentially influence other investors to consider the stock.

Risk Assessment

Risk Level: low — This filing indicates a large institutional investor has taken a significant stake, which generally reduces perceived risk due to increased institutional oversight and potential for future engagement.

Analyst Insight

A smart investor would research Standard BioTools Inc. to understand the underlying reasons for Viking Global's significant investment and consider if it aligns with their own investment thesis.

Key Numbers

• 10,000,000 — Shares Beneficially Owned (Represents the total number of common shares of Standard BioTools Inc. held by Viking Global Investors LP.)
• 9.9% — Percentage of Class (Indicates the significant ownership stake Viking Global Investors LP has in Standard BioTools Inc.)

Key Players & Entities

• Viking Global Investors LP (company) — filing entity, reporting a significant stake
• Standard BioTools Inc. (company) — subject company, whose shares were acquired
• Fluidigm Corp (company) — former name of Standard BioTools Inc.
• DAVID C. OTT (person) — group member of Viking Global
• O. ANDREAS HALVORSEN (person) — group member of Viking Global
• ROSE S. SHABET (person) — group member of Viking Global
• 10,000,000 (dollar_amount) — number of shares beneficially owned by Viking Global
• 9.9% (dollar_amount) — percentage of class beneficially owned by Viking Global
• January 5, 2024 (dollar_amount) — date of event requiring the filing

Forward-Looking Statements

• Standard BioTools Inc. stock may experience increased trading volume due to heightened investor interest following Viking Global's disclosure. (Standard BioTools Inc.) — medium confidence, target: Q1 2024
• Other institutional investors may initiate or increase their positions in Standard BioTools Inc., following Viking Global's lead. (Standard BioTools Inc.) — low confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class o
• $0.0001 — of common stock of SomaLogic, par value $0.0001 per share, outstanding as of November 2

Filing Documents

• ef20018465_sc13g.htm (SC 13G) — 396KB
• 0001140361-24-001535.txt ( ) — 398KB

(a)

Item 1(a). Name of Issuer : Standard BioTools Inc.

(b)

Item 1(b) . Address of Issuer's Principal Executive Offices : 2 Tower Place, Suite 2000, South San Francisco, CA 94080

(a)

Item 2(a) . Name of Person Filing : Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons").

(b)

Item 2(b) . Address of Principal Business Office or, if none, Residence : The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.

(c)

Item 2(c) . Citizenship : VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOD GP, and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

(d)

Item 2(d) . Titles of Classes of Securities : Common stock, $0.001 par value per share ("Common Stock")

(e)

Item 2(e) . CUSIP NUMBER : 34385P108 Item 3 . If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a : CUSIP No. 34385P108 13G Page 14 of 23 Pages (a) Broker or dealer registered under Section 15 of the Exchange Act (b) Bank as defined in Section 3(a)(6) of the Exchange Act (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E) (f) Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F) (g) Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G). (h) Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940. (j) Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). Item 4. This Statement on Schedule 13G relates to shares of Common Stock held directly by VGOP and VGOD and shares of Common Stock that the Reporting Persons have the right to acquire upon conversion of shares of Series B-2 Preferred Stock ("Series B-2 Preferred Stock") held directly by VGOP and VGOD. VGOP owns 8,164,670 shares of Common Stock and 85,612 shares of Series B-2 Preferred Stock, and VGOD owns 4,021,404 shares of Common Stock and 42,167 shares of Series B-2 Preferred Stock. The Series B-2 Preferred Stock has an initial conversion rate of 294.1176 shares of Common Stock per share

View Full Filing

View this SC 13G filing on SEC EDGAR